Tarenflurbil
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Tarenflurbil,
Mechanism of action
At proposed therapeutic concentrations, this molecule lacks anti-inflammatory activity, and does not inhibit either
, and therefore there was interest in this drug as a therapeutic agent.Clinical trials
In 2005, Myriad Genetics reported the results of its Phase II clinical trial of Flurizan; it was the largest ever Alzheimer's drug treatment trial using R-flurbiprofen.[5] Patients were split into three treatment groups, receiving placebo, 400 or 800 mg R-flurbiprofen twice daily for a year. Result from this trial showed that the drug was well tolerated, and positive trends were observed with the 800 mg twice-daily dose in patients with mild Alzheimer's disease. A subgroup of patients that were diagnosed with mild disease, and had high plasma drug levels had significantly less decline in two primary behavioral outcomes (Activities of Daily Living scale (ADCS-ADL) and Global Function (CDR-SB)). Approximately 80 patients enrolled in the optional follow-on study showed continuing benefits with R-flurbiprofen, with increasing positive trends over this period for all primary outcomes after 24 months. On March 5, 2007 Myriad reported final results of the two-year trial, showing that 42% of those 80 patients showed improvement or no decline in one or more of the three primary endpoints of cognition, global function and activities of daily living, compared to a typical 10% of patients on placebo.
A
References
- ^ www.myriad.com Archived 2007-08-02 at the Wayback Machine Update on Flurizan.
- ^ a b c Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan in Alzheimer's Disease from the Myriad Genetics website.
- PMID 12897211.
- S2CID 33985910.
- ^ Myriad Genetics Reports Results of Phase 2 Trial of Flurizan in Patients With Alzheimer's Disease, a May 2005 article from the website of Myriad Genetics
- ^ www.myriad.com Archived 2006-03-16 at the Wayback Machine FLURIZAN & Alzheimer's Disease
- Mary Ann Liebert, Inc.2008-06-15. p. 8.
External links
- Media related to Tarenflurbil at Wikimedia Commons